XOMA Corporation Spikes on Price Offering

Jacob Harper  |

Biotech company XOMA Corporation ($XOMA) announced the price of their common stock offering on Thursday that sent the price of shares on an upward trajectory.

XOMA is offering 7.6 million shares at $3.62 a share, which should net the company around $25.5 million. Also, the company is allowing underwriters a 30 day option on an additional 1.14 million shares.

The Berkeley, Ca.-based biotech firm's flagship drug (and focus of principal reserach) is called gevokizumab. The drug is a humanized monoclonal antibody which is used primarily in the treatment of diabetes. On July 22 the drug entered Phase 2 of the approval process. Gevokizumab is also currently in phase III development for treating non-infectious uveitis and Behçet’s uveitis, which are multiskeletal inflammatory disorders.

On Aug. 7, the company reported a 21 cent per-share loss for the second quarter of 2013, missing revenue estimates by 21 percent. XOMA’s stock dropped precipitously on the news, losing around 20 percent of its value. In March, the stock was thought to be the most undervalued biomed stock under $10.

XOMA is down 20.27 percent on the month, hurt by the lagging earnings for the second quarter. But with Thursday's offering, the stock shot up 11.17 percent to hit $4.47 a share.

(image courtesy of Wikimedia Commons)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
XOMA XOMA Corporation 13.65 -0.23 -1.66 56,374 Trade
OXBC Oxford Bank Corp 16.50 0.00 0.00 0

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…